Oral small-molecule GLP-1 innovator
Structure Therapeutics uses structure-based drug discovery to develop oral non-peptide GLP-1 receptor agonists — a key frontier in extending GLP-1 therapy beyond injectable peptides. Lead asset aleniglipron (GSBR-1290) is in Phase 2/3 for obesity and type 2 diabetes.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Aleniglipron (GSBR-1290) | Obesity / T2D | Phase 2/3 | Oral GLP-1 RA |
| ANPA-0073 | Pulmonary Hypertension | Phase 1 | Oral APJ agonist |
How to invest in the peptide therapeutics boom via ETFs and funds. Obesity-themed, broad biotech, and pharma mega-cap options compared for 2026.
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.